PMID- 31333461
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201001
IS  - 1663-9812 (Print)
IS  - 1663-9812 (Electronic)
IS  - 1663-9812 (Linking)
VI  - 10
DP  - 2019
TI  - New Lipid Mediators in Retinal Angiogenesis and Retinopathy.
PG  - 739
LID - 10.3389/fphar.2019.00739 [doi]
LID - 739
AB  - Retinal diseases associated with vascular destabilization and the inappropriate 
      proliferation of retinal endothelial cells have major consequences on the retinal 
      vascular network. In extreme cases, the development of hypoxia, the upregulation 
      of growth factors, and the hyper-proliferation of unstable capillaries can result 
      in bleeding and vision loss. While anti-vascular endothelial growth factor 
      therapy and laser retinal photocoagulation can be used to treat the symptoms of 
      late stage disease, there is currently no treatment available that can prevent 
      disease progression. Cytochrome P450 enzymes metabolize endogenous substrates 
      (polyunsaturated fatty acids) to bioactive fatty acid epoxides that demonstrate 
      biological activity with generally protective/anti-inflammatory and 
      insulin-sensitizing effects. These epoxides are further metabolized by the 
      soluble epoxide hydrolase (sEH) to fatty acid diols, high concentrations of which 
      have vascular destabilizing effects. Recent studies have identified increased sEH 
      expression and activity and the subsequent generation of the docosahexaenoic 
      acid-derived diol; 19,20-dihydroxydocosapentaenoic acid, as playing a major role 
      in the development of diabetic retinopathy. This review summarizes current 
      understanding of the roles of cytochrome P450 enzyme and sEH-derived PUFA 
      mediators in retinal disease.
FAU - Fleming, Ingrid
AU  - Fleming I
AD  - Institute for Vascular Signalling, Centre for Molecular Medicine, 
      Goethe-University, Frankfurt, Germany.
AD  - German Centre for Cardiovascular Research (DZHK) partner site RheinMain, 
      Frankfurt, Germany.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20190705
PL  - Switzerland
TA  - Front Pharmacol
JT  - Frontiers in pharmacology
JID - 101548923
PMC - PMC6624440
OTO - NOTNLM
OT  - 19,20-dihydroxydocosapentaenoic acid
OT  - cytochrome P450
OT  - diabetic retinopathy
OT  - epoxyeicosatrienoic acid
OT  - soluble epoxide hydrolase
EDAT- 2019/07/25 06:00
MHDA- 2019/07/25 06:01
PMCR- 2019/07/05
CRDT- 2019/07/24 06:00
PHST- 2019/04/14 00:00 [received]
PHST- 2019/06/07 00:00 [accepted]
PHST- 2019/07/24 06:00 [entrez]
PHST- 2019/07/25 06:00 [pubmed]
PHST- 2019/07/25 06:01 [medline]
PHST- 2019/07/05 00:00 [pmc-release]
AID - 10.3389/fphar.2019.00739 [doi]
PST - epublish
SO  - Front Pharmacol. 2019 Jul 5;10:739. doi: 10.3389/fphar.2019.00739. eCollection 
      2019.